Journal: Circulation research

Article Title: Population-based Screening for Atrial Fibrillation

doi: 10.1161/CIRCRESAHA.120.316341

Figure Lengend Snippet: Summary of guideline recommendations and consensus statements pertaining to AF screening

Article Snippet: 22 2002 United Kingdom Primary care All Systematic (N=1,499) Pulse assessment and lead II rhythm strip 6 months 0.8% Opportunistic (N=1,502) Clinical pulse assessment with discretionary 12-lead ECG if abnormal 6 months 0.5% Fitzmaurice et al. (SAFE) 49 2007 United Kingdom Primary care ≥ 65 Systematic (N=4,933) Pulse assessment and 12-lead ECG One-time 1.62% Opportunistic (N=4,933) Pulse assessment and 12-lead ECG if abnormal One-time 1.64% No screening (N=4,936) - - 1.04% Halcox et al. (REHEARSE-AF) 59 2017 United Kingdom Primary care or research visits > 65 Screening (N=501) Single-lead handheld ECG twice weekly 12 months 3.7% No screening (N=500) - - 1.0% Steinhubl et al. (mSToPS) 48 2018 United States Health plan enrollees ≥ 75, ≥ 55 (male with 1 AF/stroke risk factor), ≥ 65 (female with 1 AF/stroke risk factor) Immediate screening (N=1,366) Single-lead patch monitor for up to 14 days (screened period) 4 months 3.9% Delayed screening (N=1,293) Single-lead patch monitor for up to 14 days (unscreened period) 4 months 0.9% Open in a separate window Summary of randomized trials of atrial fibrillation screening table ft1 table-wrap mode="anchored" t5 Table 4. caption a7 Study Country Status N Modality Approach Endpoint DANCAVAS 74 Denmark Nearly complete 35,000 3-lead ECG One-time All-cause mortality STROKESTOP II 66 Sweden Nearly complete 8,000 Zenicor single-lead ECG Twice daily for 14 days New-onset AF Initiation of OAC SCREEN-AF 75 Canada Recently completed 856 Zio patch monitor, WatchBP oscillometric device 2 weeks at start and at 3 months New-onset AF AF-CATCH 76 China Follow-up 7,641 AliveCor single-lead ECG 1x/yr vs. 4x/yr vs. 1x/wk in 1 st month New-onset AF MonDAFIS 77 Germany Follow-up 3,470 Mobile telemetry Post-stroke, up to 7 days Oral anticoagulation D2AF 78 Netherlands Ongoing 19,200 MyDiagnostick single-lead ECG, WatchBP oscillometric device One-time New-onset AF LOOP 79 Denmark Ongoing 6,000 Implantable loop recorder 4 years continuous Stroke or systemic embolism mSToPS 48 United States Ongoing 6,000 Zio patch monitor 2–4 weeks Stroke, systemic embolism, myocardial infarction, death VITAL-AF 80 United States Ongoing 35,000 AliveCor single-lead ECG At each encounter New-onset AF GUARD-AF 56 United States Ongoing 52,000 Zio patch monitor 2 weeks Stroke Major bleeding London Pharmacy Study 81 United Kingdom Starting soon 600 Pulse palpation, AliveCor single-lead ECG One-time Test accuracy of screening modalities SAFER 82 United Kingdom Ongoing 120,000 Zenicor single-lead ECG Twice daily for 14 days Stroke Fitbit Heart Study 61 United States Ongoing 100,000 Wrist-based PPG Wearable PPG-based algorithm followed by ECG patch New-onset AF Open in a separate window Ongoing studies of AF screening

Techniques: Stripping Membranes

Journal: Circulation research

Article Title: Population-based Screening for Atrial Fibrillation

doi: 10.1161/CIRCRESAHA.120.316341

Figure Lengend Snippet: Ongoing studies of AF screening

Article Snippet: 22 2002 United Kingdom Primary care All Systematic (N=1,499) Pulse assessment and lead II rhythm strip 6 months 0.8% Opportunistic (N=1,502) Clinical pulse assessment with discretionary 12-lead ECG if abnormal 6 months 0.5% Fitzmaurice et al. (SAFE) 49 2007 United Kingdom Primary care ≥ 65 Systematic (N=4,933) Pulse assessment and 12-lead ECG One-time 1.62% Opportunistic (N=4,933) Pulse assessment and 12-lead ECG if abnormal One-time 1.64% No screening (N=4,936) - - 1.04% Halcox et al. (REHEARSE-AF) 59 2017 United Kingdom Primary care or research visits > 65 Screening (N=501) Single-lead handheld ECG twice weekly 12 months 3.7% No screening (N=500) - - 1.0% Steinhubl et al. (mSToPS) 48 2018 United States Health plan enrollees ≥ 75, ≥ 55 (male with 1 AF/stroke risk factor), ≥ 65 (female with 1 AF/stroke risk factor) Immediate screening (N=1,366) Single-lead patch monitor for up to 14 days (screened period) 4 months 3.9% Delayed screening (N=1,293) Single-lead patch monitor for up to 14 days (unscreened period) 4 months 0.9% Open in a separate window Summary of randomized trials of atrial fibrillation screening table ft1 table-wrap mode="anchored" t5 Table 4. caption a7 Study Country Status N Modality Approach Endpoint DANCAVAS 74 Denmark Nearly complete 35,000 3-lead ECG One-time All-cause mortality STROKESTOP II 66 Sweden Nearly complete 8,000 Zenicor single-lead ECG Twice daily for 14 days New-onset AF Initiation of OAC SCREEN-AF 75 Canada Recently completed 856 Zio patch monitor, WatchBP oscillometric device 2 weeks at start and at 3 months New-onset AF AF-CATCH 76 China Follow-up 7,641 AliveCor single-lead ECG 1x/yr vs. 4x/yr vs. 1x/wk in 1 st month New-onset AF MonDAFIS 77 Germany Follow-up 3,470 Mobile telemetry Post-stroke, up to 7 days Oral anticoagulation D2AF 78 Netherlands Ongoing 19,200 MyDiagnostick single-lead ECG, WatchBP oscillometric device One-time New-onset AF LOOP 79 Denmark Ongoing 6,000 Implantable loop recorder 4 years continuous Stroke or systemic embolism mSToPS 48 United States Ongoing 6,000 Zio patch monitor 2–4 weeks Stroke, systemic embolism, myocardial infarction, death VITAL-AF 80 United States Ongoing 35,000 AliveCor single-lead ECG At each encounter New-onset AF GUARD-AF 56 United States Ongoing 52,000 Zio patch monitor 2 weeks Stroke Major bleeding London Pharmacy Study 81 United Kingdom Starting soon 600 Pulse palpation, AliveCor single-lead ECG One-time Test accuracy of screening modalities SAFER 82 United Kingdom Ongoing 120,000 Zenicor single-lead ECG Twice daily for 14 days Stroke Fitbit Heart Study 61 United States Ongoing 100,000 Wrist-based PPG Wearable PPG-based algorithm followed by ECG patch New-onset AF Open in a separate window Ongoing studies of AF screening

Techniques:

Journal: Nature Reviews. Cardiology

Article Title: Smart wearable devices in cardiovascular care: where we are and how to move forward

doi: 10.1038/s41569-021-00522-7

Figure Lengend Snippet: Summary of cardiovascular clinical applications of wearable devices and key studies

Article Snippet: AF and other arrhythmias , PPG tachograms or notification algorithms and single-lead and multi-lead ECG , Apple Watch (Apple, USA), AliveCor Kardia Band and KardiaMobile (AliveCor, USA), Zio Patch (iRhythm Technologies, USA) , Prospective cohort studies , – , – , randomized controlled trials , , AF screening via ECG patches in selected high-risk individuals is feasible and clinically valuable .

Techniques: Activity Assay, Titration